SMAD2 and colorectal carcinoma: Compared to their control counterparts, we observed a lower frequency of TP53 mutations in CRC-muc and LUAD-muc (12/48 (25%) vs. 146/189 (77.2%), FDR < 0.001 and 5/35 (14.3%) vs. 49/101 (48.5%), FDR = 0.02, respectively), a higher frequency of SMAD4 and SMAD2 mutations in CRC-muc (17/48 (35.4%) vs. 14/189 (7.4%), FDR = 0.0001 and 8/48 (16.7%) vs. 2/189 (1.1%), FDR = 0.001, respectively) and a lower frequency of PIK3CA mutations in BRCA-muc (3/32 (9.4%) vs. 45/98 (45.9%), FDR = 0.006).